PBYI Puma Biotechnology Inc - Common Stock
NASDAQ · Biotechnology · SEC EDGAR で表示 ↗ 終値 10月 2, 2026 10-K/10-Q 8月 6, 2026PBYI 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
PBYI 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
バーの粒度は選択した期間に合わせて調整されます。バーの始値/高値/安値/終値を確認するにはチャートにカーソルを合わせてください。
Puma Biotechnology Inc - Common Stock について Wikipediaからの企業概要
Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
Creation
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. Cougar further developed abiraterone before the company was sold to Johnson & Johnson in 2009. Auerbach brought many Cougar employees with him after founding Puma in 2010.
Funding for development
In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate.
As part of an approximately $60 million financing round in October 2011, Puma entered into a reverse merger with the shell company Innovative Acquisitions Corp., formed in 2007. In April 2012 the company's stock began trading over the counter. In October 2012 the company raised around $138 million and its shares were listed on the New York Stock Exchange.
In 2016 Puma discovered that Robert Gadimian, senior director of regulatory affairs, had twice bought and sold stock based on his knowledge of unpublished clinical trial results; Puma quickly fired him after conducting an internal investigation and reported the insider trading to the SEC.
Approval and licensing of neratinib
In March 2016 Puma held a pre-NDA meeting with the FDA in which the FDA raised concerns about the design and conduct of clinical trials that Puma had run and recommended that Puma not file the NDA with that data.
Puma did file the NDA, and in May 2017 an FDA review panel recommended that the FDA approve neratinib but raised concerns that the intended use was too broad and should be limited to people with specific mutations. The FDA's briefing document to the panel had raised concerns about the marginal benefit of the drug and the side effects. In July 2017 the FDA approved neratinib for use in preventing the return of breast cancer after treatment that included trastuzumab and without any need for genetic testing, and with warnings about the risk of severe diarrhea. U.S. sales of neratinib totaled $200.5 million in 2018.
In January 2018 an EMA committee gave a negative review to neratinib. In June 2018 this same EMA committee recommended the approval of neratinib, which received European Commission (EC) approval in September 2018.
In 2019 Puma licensed commercialization rights in Europe and part of Africa to Pierre Fabre for an upfront payment of $60 million and milestone payments that could reach $345 million. Previously, Puma licensed rights in Greater China to CANbrdige Life Sciences, rights in Israel to Medison Pharma, rights in Canada to Knight Therapeutics, rights in South East Asian to Specialised Therapeutics and rights in Latin America to Pint Pharma.
== References ==
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か?
| 指標 | 5年トレンド | PBYI | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| P/E (TTM) | 18.35年平均 ≈5.0 | ≈5.0 | · | · | |
| P/S (TTM) | 2.15年平均 ≈0.8 | ≈0.8 | 7.3 | 割安 | |
| 株価純資産倍率 (MRQ) | 3.55年平均 ≈-6.8 | ≈-6.8 | 3.0 | 適正価格 | |
| EV / EBITDA (EV/EBITDA) | 11.05年平均 ≈26.1 | ≈26.1 | · | · | |
| 株価FCF倍率 (TTM) | 11.85年平均 ≈2.7 | ≈2.7 | · | · | |
| 株価収益率(P/CF) (TTM) | 11.85年平均 ≈2.7 | ≈2.7 | · | · | |
| EV/売上高 (TTM) | 1.75年平均 ≈0.8 | ≈0.8 | · | · | |
| EV/FCF (TTM) | 9.55年平均 ≈2.1 | ≈2.1 | · | · | |
| Price / Tangible Book (株価純資産倍率(P/TB)) | 5.4 | · | · | · |
同業他社の中央値は、指標ごとに標準化された基準で計算されており、この銘柄に表示されているTTM/MRQ基準と常に一致するとは限りません。
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
| 指標 | 5年トレンド | PBYI | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 営業利益率 (TTM) | 13.2%5年平均 ≈10.9% | ≈10.9% | -191.1% | トップクラス | |
| EBITDA Margin (EBITDAマージン) | 16.3%5年平均 ≈10.9% | ≈10.9% | -184.7% | トップクラス | |
| 税引前利益率 (TTM) | 13.5%5年平均 ≈4.9% | ≈4.9% | -113.8% | トップクラス | |
| 純利益率 (TTM) | 11.6%5年平均 ≈4.9% | ≈4.9% | -181.7% | トップクラス | |
| ROA (TTM) | 13.8%5年平均 ≈5.1% | ≈5.1% | -17.8% | トップクラス | |
| ROE (TTM) | 22.0%5年平均 ≈109.2% | ≈109.2% | -18.7% | トップクラス | |
| ROIC | 21.2%5年平均 ≈13.5% | ≈13.5% | -22.3% | トップクラス |
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
| 指標 | 5年トレンド | PBYI | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| 負債資本倍率 (MRQ) | 0.05年平均 ≈-6.5 | ≈-6.5 | · | · | |
| 流動比率 (MRQ) | 2.95年平均 ≈1.6 | ≈1.6 | 12.6 | 低流動性 | |
| クイックレシオ (MRQ) | 2.65年平均 ≈1.5 | ≈1.5 | 2.9 | 低流動性 | |
| 長期負債/株主資本 (MRQ) | 0.05年平均 ≈-6.7 | ≈-6.7 | · | · |
成長 収益、EPS、純利益の成長率:前年比、3年CAGR、5年CAGR
| 指標 | 5年トレンド | PBYI | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Revenue YoY (収益(前年比)) | -0.91%5年平均 ≈0.56% | ≈0.56% | · | · | |
| Revenue CAGR 3Y (収益(3年CAGR)) | 0.05%5年平均 ≈-0.50% | ≈-0.50% | · | · | |
| Revenue CAGR 5Y (収益(5年CAGR)) | 0.29% | · | · | · | |
| EPS YoY | -1.6% | · | · | · | |
| Net Income YoY (純利益(前年比)) | 2.8%5年平均 ≈359831.0% | ≈359831.0% | · | · | |
| Net Income CAGR 3Y (純利益年平均成長率 3年) | 2396.3% | · | · | · |
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
| 指標 | 5年トレンド | PBYI | 5年平均 | 競合中央値 | 結論 |
|---|---|---|---|---|---|
| Asset Turnover (総資産回転率) | 1.15年平均 ≈1.0 | ≈1.0 | 0.1 | トップクラス | |
| Inventory Turnover (棚卸資産回転率) | 8.25年平均 ≈9.7 | ≈9.7 | · | · | |
| Receivables Turnover (売掛金回転率) | 5.35年平均 ≈6.3 | ≈6.3 | · | · | |
| Revenue / Employee (年間売上高 ÷ 従業員数(yfinanceの報告ヘッドカウント)。派生値 — SEC-XBRLの保存概念ではありません。) | ≈$1.3M | · | · | · |
バリュエーション · ≈ 5年平均 · 業界中央値 · 中央値に対する評価
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
| 期間 | レポート | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|---|
| 2026年6月30日 | 8月 5, 2026 | $0.16 | $0.04 | 292.2% |
| 2026年3月31日 | $-0.07 | $-0.13 | 47.2% | |
| 2025年12月31日 | $0.26 | $0.23 | 12.3% | |
| 2025年9月30日 | $0.17 | $0.05 | 270.4% | |
| 2025年6月30日 | $0.12 | $0.10 | 14.6% | |
| 2025年3月31日 | $0.06 | $-0.02 | 394.1% |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Cost of Revenue | $58M | $64M | $63M | $55M | $64M | $39M | $37M | $35M | $6M | |
| R&D Expense | · | · | · | · | $72M | $98M | $133M | $165M | $208M | |
| SG&A Expense | $71M | $80M | $90M | $90M | $116M | $118M | $142M | $146M | $107M | |
| Operating Expenses | $191M | $200M | $203M | $204M | $252M | $256M | $311M | $346M | $320M | |
| Operating Income | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M | |
| Interest Expense | · | · | $13M | $12M | $13M | $14M | $15M | $11M | $720.0K | |
| Interest Income | $4M | $5M | $3M | $813.0K | $160.0K | $489.0K | $3M | $2M | $1M | |
| Other Non-op | $1M | $862.0K | $759.0K | $-28.0K | $292.0K | $367.0K | $128.0K | $-714.0K | $-101.0K | |
| Pretax Income | $36M | $24M | $23M | $457.0K | $-29M | $-60M | $-76M | $-114M | · | |
| Income Tax | $5M | $-6M | $1M | $455.0K | $324.0K | $207.0K | $53.0K | $17.0K | $0 | |
| Net Income | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| EPS (Basic) | $0.62 | $0.62 | $0.46 | $0.00 | $-0.72 | $-1.52 | $-75595.00 | · | · | |
| EPS (Diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · | |
| Shares (Basic) | 50,011,485 | 48,648,701 | 47,134,331 | 44,674,501 | 40,638,852 | 39,576,107 | · | · | · | |
| Shares (Diluted) | 50,653,283 | 49,100,433 | 47,550,852 | 44,929,998 | 40,638,852 | 39,576,107 | · | · | · | |
| EBITDA | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M |
貸借対照表
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30M | $69M | $85M | $76M | $63M | $85M | $60M | $108M | $82M | |
| Short-term Investments | $68M | $32M | $11M | $5M | $19M | $8M | $52M | $57M | · | |
| Receivables | $54M | $32M | $48M | $40M | $33M | $26M | $29M | $21M | $10M | |
| Inventory | $6M | $9M | $7M | $5M | $7M | $3M | $3M | $3M | $2M | |
| Prepaid Expense | $4M | $6M | $4M | $6M | $9M | $11M | $13M | $12M | $13M | |
| Other Current Assets | $256.0K | $91.0K | $912.0K | $2M | $447.0K | $4M | $323.0K | $2M | · | |
| Current Assets | $163M | $148M | $156M | $134M | $140M | $146M | $166M | $203M | $106M | |
| PP&E (Net) | $187.0K | $515.0K | $855.0K | $1M | $2M | $2M | $3M | $4M | $4M | |
| PP&E (Gross) | $5M | $8M | $9M | $9M | $9M | $9M | $9M | $9M | $9M | |
| Accum. Depreciation | $5M | $8M | $8M | $7M | $7M | $6M | $6M | $5M | $4M | |
| Intangibles | $41M | $51M | $61M | $71M | $66M | $74M | $40M | $44M | $48M | |
| Total Assets | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Accounts Payable | $5M | $6M | $7M | $6M | $11M | $12M | $19M | $21M | $28M | |
| Accrued Liabilities | $50M | $37M | $53M | $53M | $93M | $61M | $69M | $46M | $31M | |
| Current Liabilities | $81M | $96M | $99M | $77M | $110M | $114M | $91M | $67M | $58M | |
| Capital Leases | $5M | $1M | $7M | $12M | $16M | $20M | $23M | · | · | |
| Other Non-current Liabilities | $0 | $121.0K | $121.0K | · | · | · | · | · | · | |
| Total Liabilities | $86M | $121M | $177M | $200M | $229M | $250M | $217M | $225M | $112M | |
| Long-term Debt | $23M | $68M | $102M | $102M | $102M | $84M | $95M | $152M | $48M | |
| Total Debt | $23M | $67M | $100M | $98M | $97M | $98M | · | · | · | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.28B | $-1.31B | $-1.35B | $-1.37B | $-1.37B | $-1.34B | $-1.28B | $-1.20B | $-1.09B | |
| AOCI | $36.0K | $6.0K | $-4.0K | $0 | $-2.0K | $0 | $62.0K | $-12.0K | · | |
| Stockholders' Equity | $130M | $92M | $53M | $22M | $-2M | $-6M | $17M | $34M | $53M | |
| Liabilities + Equity | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Shares Outstanding | 50,408,023 | 49,105,834 | 47,646,787 | 46,345,660 | 41,175,507 | 40,086,387 | 39,203,304 | 38,325,037 | 37,594,851 |
キャッシュフロー
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11M | $12M | $12M | $10M | $11M | $10M | $8M | $7M | $3M | |
| Stock-based Comp | $7M | $8M | $10M | $12M | $33M | $37M | $57M | $87M | $109M | |
| Deferred Tax | $3M | $-7M | $0 | $0 | · | · | · | · | · | |
| Amort. of Intangibles | $10M | $10M | $8M | $8M | $8M | $6M | $4M | $4M | $2M | |
| Operating Cash Flow | $42M | $39M | $27M | $-16M | $21M | $773.0K | $22M | $-24M | $-172M | |
| CapEx | $71.0K | $56.0K | $140.0K | $0 | $0 | $46.0K | $306.0K | $439.0K | $431.0K | |
| Investing Cash Flow | $-36M | $-20M | $-19M | $7M | $-11M | $33M | $5M | $-58M | $-15M | |
| Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Financing Cash Flow | $-45M | $-34M | $0 | $12M | $-32M | $-10M | $-67M | $108M | $75M | |
| Net Change in Cash | $-40M | $-15M | $8M | $4M | $-22M | $24M | $-40M | $27M | $-113M | |
| Taxes Paid | $1M | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $42M | $39M | $27M | $-16M | $21M | · | · | $-25M | $-173M | |
| Levered FCF | · | · | $14M | $-16M | $8M | · | · | · | · |
収益性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| Net Margin | 13.6% | 13.1% | 9.2% | 0.00% | -11.5% | -26.7% | -27.8% | -45.2% | -1054.6% | |
| Pretax Margin | 15.7% | 10.5% | 9.6% | 0.20% | -11.4% | -26.6% | · | · | · | |
| EBITDA Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| ROA | 14.5% | 13.6% | 9.5% | 0.00% | -12.4% | -25.0% | -30.6% | -53.5% | -139.6% | |
| ROE | 26.5% | 37.1% | 46.8% | 0.01% | 435.8% | 1873.7% | -436.4% | -283.2% | -221.9% | |
| ROIC | 21.2% | 24.4% | 20.3% | 0.09% | 1.4% | -33.0% | · | · | · |
流動性と支払能力
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 | 1.3 | 1.8 | 3.0 | 1.8 | |
| Quick Ratio | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 | 1.0 | 1.5 | 2.8 | 1.6 | |
| Debt / Equity | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 | -16.5 | · | · | · | |
| LT Debt / Equity | 0.0 | 0.2 | 1.2 | 4.5 | -39.7 | -14.1 | · | · | · | |
| Interest Coverage | · | · | 2.4 | 2.0 | 0.1 | -2.2 | -2.6 | -8.6 | -406.1 |
効率性
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 1.0 | 1.0 | 1.0 | 1.1 | 0.9 | 1.1 | 1.2 | 0.1 | |
| Inventory Turnover | 8.2 | 8.2 | 10.8 | 9.5 | 12.1 | · | · | 14.9 | 5.5 | |
| Receivables Turnover | 5.3 | 5.8 | 5.3 | 6.3 | 8.7 | 8.3 | 11.0 | 16.5 | 5.7 |
1株あたり
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.59 | $1.88 | $1.12 | $0.52 | $-0.06 | $-0.15 | $0.45 | $0.90 | $1.42 | |
| Revenue / Share | $4.51 | $4.69 | $4.96 | $5.08 | · | · | · | · | · | |
| Cash Flow / Share | $0.83 | $0.79 | $0.57 | $-0.35 | · | · | · | · | · | |
| Cash / Share | $0.59 | $1.41 | $1.78 | $1.85 | $1.57 | $2.13 | $1.53 | $2.83 | $2.17 | |
| EPS (TTM) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · |
成長率
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.91% | -2.2% | 3.3% | -9.9% | 12.5% | · | · | · | · | |
| Revenue CAGR 3Y | 0.05% | -3.1% | 1.5% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 0.29% | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.6% | 37.8% | · | · | · | · | · | · | · | |
| Net Income YoY | 2.8% | 40.2% | 1079450.0% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 2396.3% | · | · | · | · | · | · | · | · |
バリュエーション(TTM)
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Net Income TTM | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| Market Cap | $300M | $150M | $206M | $174M | $122M | $411M | $343M | $780M | $3.72B | |
| Enterprise Value | $225M | $116M | $210M | $191M | $137M | $416M | · | · | · | |
| P/E | 9.8 | 4.9 | 9.6 | · | -4.2 | -6.8 | · | · | · | |
| P/S | 1.3 | 0.6 | 0.9 | 0.8 | 0.5 | 1.8 | 1.3 | 3.1 | 134.2 | |
| P/B | 2.3 | 1.6 | 3.9 | 8.1 | -49.8 | -69.1 | 19.6 | 22.7 | 69.7 | |
| P / Tangible Book | 3.4 | 3.7 | · | · | · | · | · | · | · | |
| P / Cash Flow | 7.2 | 3.8 | 7.6 | -11.0 | 5.9 | 532.1 | 15.3 | -32.4 | -21.5 | |
| P / FCF | 7.2 | 3.9 | 7.7 | -11.0 | 5.9 | · | · | -31.8 | -21.5 | |
| EV / EBITDA | 6.0 | 3.7 | 6.4 | 8.1 | 106.1 | -13.7 | · | · | · | |
| EV / FCF | 5.4 | 3.0 | 7.8 | -12.1 | 6.6 | · | · | · | · | |
| EV / Revenue | 1.0 | 0.5 | 0.9 | 0.8 | 0.5 | 1.8 | · | · | · | |
| Earnings Yield | 10.2% | 20.3% | 10.4% | 0.00% | -23.7% | -14.8% | · | · | · |
損益計算書
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $45M | $75M | $54M | $52M | $46M | $59M | $81M | $47M | $44M | $72M | $56M | $55M | $53M | $66M | $57M | |
| Cost of Revenue | $12M | $10M | $23M | $12M | $12M | $11M | $14M | $29M | $11M | $11M | $24M | $13M | $12M | $13M | $17M | $12M | |
| SG&A Expense | $18M | $18M | $18M | $17M | $18M | $18M | $17M | $17M | $25M | $22M | $20M | $23M | $24M | $22M | $25M | $24M | |
| Operating Expenses | $49M | $49M | $58M | $45M | $46M | $42M | $46M | $58M | $49M | $46M | $57M | $48M | $50M | $48M | $56M | $55M | |
| Operating Income | $8M | $-4M | $17M | $10M | $7M | $4M | $13M | $22M | $-2M | $-2M | $15M | $9M | $5M | $4M | $10M | $2M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $3M | · | $3M | $3M | $3M | · | $3M | |
| Interest Income | $831.0K | $1M | $977.0K | $1M | $956.0K | $1M | $1M | $1M | $1M | $972.0K | $719.0K | $689.0K | $660.0K | $537.0K | $519.0K | $216.0K | |
| Other Non-op | $9.0K | $130.0K | $143.0K | $115.0K | $410.0K | $359.0K | $268.0K | $347.0K | $156.0K | $91.0K | $641.0K | $74.0K | $86.0K | $-42.0K | $-204.0K | $64.0K | |
| Pretax Income | $8M | $-3M | $17M | $9M | $6M | $3M | $12M | $21M | $-4M | $-5M | $13M | $6M | $2M | $2M | $-5M | $-293.0K | |
| Income Tax | · | · | · | · | · | · | $-7M | $291.0K | $378.0K | $220.0K | $536.0K | $213.0K | $187.0K | $147.0K | $294.0K | $67.0K | |
| Net Income | $8M | $-4M | $13M | $9M | $6M | $3M | $19M | $20M | $-5M | $-5M | $12M | $6M | $2M | $1M | $-6M | $-360.0K | |
| EPS (Basic) | $0.16 | $-0.07 | $0.26 | $0.18 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.26 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| EPS (Diluted) | $0.16 | $-0.07 | $0.26 | $0.17 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.25 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| Shares (Basic) | 50,939,946 | 50,845,130 | · | 50,339,456 | 49,700,217 | 49,595,697 | · | 49,008,464 | 48,292,414 | 48,189,256 | · | 47,520,338 | 46,759,062 | 46,636,083 | · | 45,567,739 | |
| Shares (Diluted) | 52,596,589 | 50,845,130 | · | 50,929,893 | 50,144,704 | 49,906,341 | · | 49,173,361 | 48,292,414 | 48,189,256 | · | 47,819,234 | 47,201,185 | 47,157,904 | · | 45,567,739 | |
| EBITDA | $8M | $-4M | · | $10M | $7M | · | · | $22M | $-2M | $-2M | · | $9M | $5M | $4M | · | $2M |
貸借対照表
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37M | $36M | $30M | $54M | $55M | $63M | $69M | $67M | $67M | $77M | · | $82M | $60M | $61M | · | $78M | |
| Short-term Investments | $57M | $65M | $68M | $41M | $41M | $30M | $32M | $29M | $30M | $30M | · | $3M | $14M | $10M | · | $0 | |
| Receivables | $34M | $26M | $54M | $34M | $26M | $25M | $32M | $55M | $28M | $25M | · | $29M | $31M | $31M | · | $28M | |
| Inventory | $13M | $9M | $6M | $9M | $9M | $9M | $9M | $3M | $9M | $7M | · | $6M | $8M | $4M | · | $5M | |
| Prepaid Expense | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $3M | $3M | $4M | · | $4M | $5M | $5M | · | $7M | |
| Other Current Assets | $199.0K | $196.0K | $256.0K | $230.0K | $73.0K | $98.0K | $91.0K | $236.0K | $241.0K | $255.0K | · | $2M | $573.0K | $449.0K | · | $4M | |
| Current Assets | $145M | $142M | $163M | $144M | $137M | $133M | $148M | $157M | $138M | $143M | · | $125M | $119M | $112M | · | $122M | |
| PP&E (Net) | $103.0K | $124.0K | $187.0K | $305.0K | $388.0K | $474.0K | $515.0K | $601.0K | $680.0K | $757.0K | · | $907.0K | $977.0K | $1M | · | $1M | |
| PP&E (Gross) | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $9M | $9M | $9M | · | $9M | $9M | $9M | · | $9M | |
| Accum. Depreciation | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | $7M | |
| Intangibles | · | · | $41M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Accounts Payable | $3M | $8M | $5M | $6M | $5M | $6M | $6M | $8M | $14M | $9M | · | $5M | $8M | $9M | · | $15M | |
| Accrued Liabilities | $45M | $38M | $50M | $37M | $32M | $27M | $37M | $51M | $39M | $38M | · | $34M | $35M | $34M | · | $40M | |
| Current Liabilities | $50M | $60M | $81M | $83M | $79M | $87M | $96M | $110M | $104M | $98M | · | $67M | $60M | $48M | · | $60M | |
| Capital Leases | $4M | $5M | $5M | $5M | $0 | $0 | $1M | $3M | $4M | $6M | · | $8M | $10M | $11M | · | $13M | |
| Other Non-current Liabilities | · | · | $0 | $0 | $0 | $0 | $121.0K | $121.0K | $121.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $54M | $64M | $86M | $88M | $90M | $99M | $121M | $150M | $156M | $163M | · | $165M | $170M | $170M | · | $177M | |
| Long-term Debt | $0 | $11M | $23M | $34M | $45M | $57M | $67M | $79M | $91M | $102M | · | $102M | $102M | $102M | · | $102M | |
| Total Debt | $0 | $11M | · | $34M | $45M | · | · | $78M | $89M | $100M | · | $99M | $99M | $99M | · | $98M | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | · | $5.0K | $5.0K | $5.0K | · | $5.0K | |
| Retained Earnings | $-1.28B | $-1.29B | $-1.28B | $-1.30B | $-1.31B | $-1.31B | $-1.31B | $-1.33B | $-1.35B | $-1.35B | · | $-1.36B | $-1.36B | $-1.37B | · | $-1.36B | |
| AOCI | $-45.0K | $-31.0K | $36.0K | $19.0K | $-14.0K | $-11.0K | $6.0K | $26.0K | $-32.0K | $-26.0K | · | $-4.0K | $-6.0K | · | · | $0 | |
| Stockholders' Equity | $139M | $128M | $130M | $115M | $105M | $97M | $92M | $71M | $49M | $51M | $53M | $39M | $30M | $26M | $22M | $22M | |
| Liabilities + Equity | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Shares Outstanding | 51,102,687 | 50,879,204 | 50,408,023 | 50,384,274 | 49,892,725 | 49,615,174 | 49,105,834 | 49,067,348 | 48,460,120 | 48,214,663 | 47,646,787 | 47,542,790 | 46,947,153 | 46,663,599 | 46,345,660 | 45,608,814 |
キャッシュフロー
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $2M | $3M | $3M | $3M | |
| Amort. of Intangibles | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $800.0K | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $2M | $15M | $14M | $10M | $14M | $4M | $16M | $11M | $1M | $11M | $10M | $11M | $3M | $3M | $8M | $17M | |
| CapEx | $0 | $0 | $-36.0K | $26.0K | $20.0K | $61.0K | $16.0K | $20.0K | $20.0K | $0 | $45.0K | $27.0K | · | · | $0 | $0 | |
| Investing Cash Flow | $8M | $2M | $-27M | $506.0K | $-11M | $2M | $-2M | $259.0K | $703.0K | $-19M | $-8M | $11M | $-5M | $-17M | $-12M | $8M | |
| Financing Cash Flow | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $0 | $0 | $0 | $0 | $0 | $2M | $-53.0K | |
| Net Change in Cash | $-2M | $7M | $-24M | $-1M | $-8M | $-6M | $2M | $114.0K | $-10M | $-8M | $2M | $22M | $-1M | $-15M | $-2M | $25M | |
| Free Cash Flow | · | $15M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
収益性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| Net Margin | 14.5% | -8.4% | · | 16.2% | 11.2% | · | · | 25.2% | -9.6% | -11.0% | · | 10.3% | 3.9% | 2.6% | · | -0.63% | |
| Pretax Margin | 14.6% | -7.6% | · | 17.0% | 11.8% | · | · | 25.6% | -8.8% | -10.5% | · | 10.7% | 4.2% | 2.9% | · | -0.51% | |
| EBITDA Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| ROA | 4.2% | -1.9% | · | 4.2% | 2.9% | · | · | 9.6% | -2.2% | -2.4% | · | 2.9% | 1.1% | 0.71% | · | -0.17% | |
| ROE | 6.7% | -3.3% | · | 9.5% | 7.6% | · | · | 37.0% | -11.5% | -12.5% | · | 19.0% | 8.5% | 8.5% | · | -6.4% | |
| ROIC | · | · | · | · | · | · | · | 14.6% | -1.7% | -1.6% | · | 6.0% | 3.5% | 3.2% | · | 2.5% |
流動性と支払能力
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | 2.4 | · | 1.7 | 1.7 | · | · | 1.4 | 1.3 | 1.5 | · | 1.9 | 2.0 | 2.3 | · | 2.0 | |
| Quick Ratio | 2.6 | 2.1 | · | 1.5 | 1.5 | · | · | 1.4 | 1.2 | 1.3 | · | 1.7 | 1.8 | 2.1 | · | 1.8 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.4 | · | · | 1.1 | 1.8 | 2.0 | · | 2.6 | 3.3 | 3.8 | · | 4.4 | |
| LT Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.1 | · | · | 0.5 | 0.9 | 1.1 | · | 2.0 | 2.9 | 3.8 | · | 4.4 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -0.7 | · | 2.6 | 1.5 | 1.3 | · | 0.8 |
効率性
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.3 | · | · | 0.4 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Inventory Turnover | 1.1 | 1.2 | · | 2.0 | 1.4 | · | · | 7.0 | 1.3 | 2.0 | · | 2.4 | 1.7 | 2.4 | · | 2.0 | |
| Receivables Turnover | 1.9 | 1.7 | · | 1.2 | 1.9 | · | · | 1.9 | 1.6 | 1.6 | · | 2.0 | 1.7 | 1.8 | · | 2.2 |
1株あたり
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.71 | $2.52 | · | $2.29 | $2.10 | · | · | $1.45 | $1.00 | $1.06 | · | $0.81 | $0.65 | $0.55 | · | $0.49 | |
| Revenue / Share | $1.07 | $0.88 | · | $1.07 | $1.05 | · | · | $1.64 | $0.97 | $0.91 | · | $1.17 | $1.16 | $1.12 | · | $1.25 | |
| Cash Flow / Share | · | $0.30 | · | · | · | · | · | · | · | $0.23 | · | · | · | $0.06 | · | · | |
| Cash / Share | $0.71 | $0.71 | · | $1.06 | $1.10 | · | · | $1.37 | $1.39 | $1.59 | · | $1.72 | $1.28 | $1.32 | · | $1.71 | |
| EPS (TTM) | $0.52 | $0.48 | · | $0.75 | $0.99 | $0.28 | · | $0.47 | $0.18 | $0.32 | · | $0.08 | $-0.05 | $0.11 | · | $0.22 |
バリュエーション(TTM)
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $231M | $227M | · | $212M | $238M | $217M | · | $244M | $219M | $227M | · | $229M | $230M | $235M | · | $218M | |
| Net Income TTM | $27M | $24M | · | $37M | $48M | $14M | · | $23M | $9M | $15M | · | $4M | $-2M | $5M | · | $10M | |
| Market Cap | $414M | $325M | · | $268M | $171M | · | · | $125M | $158M | $256M | · | $125M | $166M | $144M | · | $108M | |
| Enterprise Value | $321M | $235M | · | $207M | $120M | · | · | $106M | $150M | $248M | · | $139M | $190M | $172M | · | $128M | |
| P/E | 15.6 | 13.3 | · | 7.1 | 3.5 | 10.6 | · | 5.4 | 18.1 | 16.6 | · | 32.9 | -70.6 | 28.1 | · | 10.8 | |
| P/S | 1.8 | 1.4 | · | 1.3 | 0.7 | · | · | 0.5 | 0.7 | 1.1 | · | 0.5 | 0.7 | 0.6 | · | 0.5 | |
| P/B | 3.0 | 2.5 | · | 2.3 | 1.6 | · | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Tangible Book | 3.0 | 2.5 | · | 2.3 | 1.6 | 1.5 | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Cash Flow | · | 21.1 | · | · | · | · | · | · | · | 22.7 | · | · | · | 54.6 | · | · | |
| EV / Revenue | 1.4 | 1.0 | · | 1.0 | 0.5 | · | · | 0.4 | 0.7 | 1.1 | · | 0.6 | 0.8 | 0.7 | · | 0.6 | |
| Earnings Yield | 6.4% | 7.5% | · | 14.1% | 28.9% | 9.5% | · | 18.4% | 5.5% | 6.0% | · | 3.0% | -1.4% | 3.6% | · | 9.3% |
最新期間は左側 · null値は・として表示
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 収益 | $228M | $230M | $236M | $228M | $253M |
| 営業利益率 % | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% |
| 純利益 | $31M | $30M | $22M | $2.0K | $-29M |
| 希薄化後EPS | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 負債資本倍率 | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 |
| 流動比率 | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 |
| クイックレシオ | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 |
| 指標 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $42M | $39M | $27M | $-16M | $21M |
機関投資家(13F) 172 提出者 · $307.7M合計 · 時点 2026年9月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 22 (-8 前期比) | 15 (-1 前期比) | 60 (-1 前期比) | 53 (+16 前期比) | +896K |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | $33,504,835 | 4,131,299 | 10.89% | 株式数 |
| BlackRock, Inc. | $30,856,410 | 3,804,736 | 10.03% | 株式数 |
| VANGUARD GROUP INC | $22,596,600 | 3,797,748 | 7.34% | 株式数 |
| AMERICAN CENTURY COMPANIES INC | $18,815,168 | 2,319,996 | 6.11% | 株式数 |
| RENAISSANCE TECHNOLOGIES LLC | $14,891,687 | 1,836,213 | 4.84% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14,887,065 | 1,835,643 | 4.84% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $14,805,608 | 1,825,599 | 4.81% | 株式数 |
| DIMENSIONAL FUND ADVISORS LP | $12,311,629 | 1,518,014 | 4.00% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $10,864,667 | 1,339,405 | 3.53% | 株式数 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $9,113,880 | 1,123,783 | 2.96% | 株式数 |
| STATE STREET CORP | $7,722,058 | 952,165 | 2.51% | 株式数 |
| KENNEDY CAPITAL MANAGEMENT LLC | $7,082,082 | 873,253 | 2.30% | 株式数 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $6,420,006 | 791,616 | 2.09% | 株式数 |
| RITHOLTZ WEALTH MANAGEMENT | $6,080,862 | 749,798 | 1.98% | 株式数 |
| AQR CAPITAL MANAGEMENT LLC | $5,881,307 | 725,192 | 1.91% | 株式数 |
| GOLDMAN SACHS GROUP INC | $5,426,855 | 669,156 | 1.76% | 株式数 |
| NORTHERN TRUST CORP | $5,290,851 | 652,386 | 1.72% | 株式数 |
| Connor, Clark & Lunn Investment Management Ltd. | $5,214,292 | 642,946 | 1.69% | 株式数 |
| UBS Group AG | $5,164,131 | 636,761 | 1.68% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $4,884,166 | 602,240 | 1.59% | 株式数 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $4,318,170 | 532,450 | 1.40% | 株式数 |
| SEI INVESTMENTS CO | $3,395,406 | 418,669 | 1.10% | 株式数 |
| GLOBEFLEX CAPITAL L P | $3,104,565 | 382,807 | 1.01% | 株式数 |
| Bank of New York Mellon Corp | $2,925,553 | 360,734 | 0.95% | 株式数 |
| D. E. Shaw & Co., Inc. | $2,565,542 | 316,343 | 0.83% | 株式数 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $2,506,850 | 309,106 | 0.81% | 株式数 |
| Invesco Ltd. | $2,441,127 | 301,002 | 0.79% | 株式数 |
| Russell Investments Group, Ltd. | $2,207,818 | 272,234 | 0.72% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $2,182,158 | 269,070 | 0.71% | 株式数 |
| MORGAN STANLEY | $2,154,584 | 265,670 | 0.70% | 株式数 |
| FEDERATED HERMES, INC. | $2,033,712 | 250,766 | 0.66% | 株式数 |
| Empowered Funds, LLC | $1,786,763 | 220,316 | 0.58% | 株式数 |
| PANAGORA ASSET MANAGEMENT INC | $1,764,290 | 217,545 | 0.57% | 株式数 |
| PRUDENTIAL FINANCIAL INC | $1,732,288 | 213,599 | 0.56% | 株式数 |
| JPMORGAN CHASE & CO | $1,730,866 | 211,339 | 0.56% | 株式数 |
| FMR LLC | $1,714,811 | 211,444 | 0.56% | 株式数 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,526,562 | 188,232 | 0.50% | 株式数 |
| FRANKLIN RESOURCES INC | $1,395,001 | 172,010 | 0.45% | 株式数 |
| Prospera Financial Services Inc | $1,287,530 | 158,762 | 0.42% | 株式数 |
| Haven Private, LLC | $1,203,913 | 148,448 | 0.39% | 株式数 |
| TWO SIGMA INVESTMENTS, LP | $1,140,161 | 140,587 | 0.37% | 株式数 |
| FIRST TRUST ADVISORS LP | $1,055,970 | 130,206 | 0.34% | 株式数 |
| Round Rock Advisors LLC | $1,045,476 | 128,912 | 0.34% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1,040,051 | 128,243 | 0.34% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $1,022,598 | 126,091 | 0.33% | 株式数 |
| STRS OHIO | $686,106 | 84,600 | 0.22% | 株式数 |
| Nuveen, LLC | $667,437 | 82,298 | 0.22% | 株式数 |
| EVERGREEN CAPITAL MANAGEMENT LLC | $597,960 | 73,731 | 0.19% | 株式数 |
| CANADA PENSION PLAN INVESTMENT BOARD | $596,085 | 73,500 | 0.19% | 株式数 |
| Trexquant Investment LP | $585,729 | 72,223 | 0.19% | 株式数 |
アクティビストおよび5%超のオーナー 7保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図(アクティビストの保有、取締役会キャンペーン、M&A)を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Alan H. Auerbach ×6 提出書類 | 2022年12月13日 | · | 初回提出 | 受動的投資 | SEC |
| Kapil Munjal 2) | 2011年10月4日 | · | 初回提出 | · | SEC |
| Faraaz Siddiqi 2) | 2011年10月4日 | · | 初回提出 | · | SEC |
| Robert Johnson 2) | 2011年10月4日 | · | 初回提出 | · | SEC |
| Robert Johnson | 2007年11月21日 | · | 初回提出 | · | SEC |
| 未開示の報告者 | 2007年11月19日 | · | 初回提出 | · | SEC |
| Faraaz Siddiqi | 2007年11月19日 | · | 初回提出 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
企業インサイダー 24 人のインサイダー · 10人の役員 · 12人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Alan H Auerbach | President and CEO | 2026年7月6日 S | 7,261,671 | 0 | 3 | $-568,748 |
| Maximo F Nougues | Chief Financial Officer | 2026年7月6日 S | 230,637 | 0 | 3 | $-141,703 |
| Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | 2026年7月6日 S | 196,841 | 0 | 3 | $-122,564 |
| Jeffrey Jerome Ludwig | Chief Commercial Officer | 2025年2月7日 A | 156,792 | 0 | 0 | $0 |
| Alvin F Wong | Chief Scientific Officer | 2024年2月12日 A | 141,241 | 0 | 0 | $0 |
| Richard Paul Bryce | Title of Reporting Person: Chief Medical and Scientific Officer | 2021年4月5日 S | 121,662 | 0 | 0 | $0 |
| Steven Lo | Chief Commercial Officer | 2019年7月22日 S | 19,557 | 0 | 0 | $0 |
| Charles R Eyler | Title of Reporting Person: Senior Vice President, Finance and Administration and Treasurer | 2019年2月4日 S | 31,957 | 0 | 0 | $0 |
| Robert Charnas | The Reporting Person is the Senior Vice President of Regulatory Affairs and Project Management of the Issuer. | 2017年2月16日 A | 26,453 | 0 | 0 | $0 |
| Richard Benton Phillips | The Reporting Person is the Interim Head of Regulatory Affairs, Quality Assurance and Pharmacovigilance of the Issuer. | 2016年4月15日 A | · | 0 | 0 | $0 |
| Alessandra Cesano | 取締役 | 2026年9月14日 M | 56,700 | 0 | 1 | $-566,808 |
| Troy Edward Wilson | 取締役 | 2026年9月14日 S | 54,750 | 0 | 2 | $-123,260 |
| Brian M Stuglik | 取締役 | 2026年6月12日 S | 113,858 | 0 | 1 | $-58,320 |
| Allison Dorval | 取締役 | 2026年6月12日 S | 90,780 | 0 | 1 | $-83,592 |
| Adrian Senderowicz | 取締役 | 2026年6月12日 S | 27,000 | 0 | 1 | $-194,400 |
| Jay M Moyes | 取締役 | 2026年6月12日 S | 58,322 | 0 | 1 | $-158,840 |
| MILLER MICHAEL PATRICK | 取締役 | 2026年6月11日 A | 81,000 | 0 | 1 | $-97,200 |
| Ann Calby Miller | 取締役 | 2021年6月15日 A | 40,732 | 0 | 0 | $0 |
| Hugh O'Dowd | 取締役 | 2020年6月9日 A | 25,748 | 0 | 0 | $0 |
| Frank Zavrl | 取締役 | 2020年6月9日 A | 50,993 | 0 | 0 | $0 |
| Thomas Malley | 取締役 | 2014年12月15日 A | 156,551 | 0 | 0 | $0 |
| Faraaz Siddiqi | · | 2011年10月4日 D | 0 | 0 | 0 | $0 |
| Kapil Munjal | · | 2011年10月4日 D | 0 | 0 | 0 | $0 |
| Robert Andrew Johnson | · | 2011年10月4日 D | 0 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー;純額=公開市場のP/Sのみ
ETF保有状況 25のETFが保有
ウェイトは直接株式保有(N-PORT)のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| ROSC · Lattice Strategies Trust | 0.71% | 55,155 NS | 2026年7月31日 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0.56% | 231,071 SH | 2026年10月1日 | 日次 |
| IWC · iShares Trust | 0.10% | 149,805 SH | 2026年9月11日 | 日次 |
| VFQY · VANGUARD WELLINGTON FUND | 0.06% | 34,260 SH | 2026年8月19日 | 日次 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.03% | 3,640 SH | 2026年10月1日 | 日次 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 55,175 SH | 2026年10月1日 | 日次 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 32,358 SH | 2026年8月19日 | 日次 |
| IWM · iShares Trust | 0.01% | 1,181,450 SH | 2026年9月11日 | 日次 |
| RSSL · Global X Funds | 0.01% | 21,135 NS | 2026年7月31日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.01% | 16,014 SH | 2026年8月19日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 254,380 SH | 2026年8月19日 | 日次 |
| DFAT · Dimensional ETF Trust | 0.01% | 172,951 NS | 2026年7月31日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.01% | 170,404 NS | 2026年7月31日 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.01% | 81,441 NS | 2026年7月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.01% | 3,611 NS | 2026年7月31日 | N-PORT |
| IWO · iShares Trust | 0.00% | 67,004 SH | 2026年9月11日 | 日次 |
| DCOR · Dimensional ETF Trust | 0.00% | 6,348 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 12,537 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 15,090 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 12,376 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 446,899 SH | 2026年8月19日 | 日次 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,343,121 SH | 2026年8月19日 | 日次 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.00% | 7,680 SH | 2026年8月19日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,979 SH | 2026年8月19日 | 日次 |
| IWN · iShares Trust | · | 357,993 SH | 2026年9月11日 | 日次 |
PBYI アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
12ヶ月目標株価
1 アナリスト · 2026-08-18平均値ターゲット $6.00 -36.9%
同業他社比較(GICSサブインダストリー) 主要メトリクスとセクターピアの比較
FY基準、価格は各社の直近年度末終値。
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| PROK | · | · | 1075.0% | -7725.2% | 6.9% | · |
| MNPR | · | · | · | · | · | · |
| CAPR | $1.66B | -12.8 | -11.6% | · | -51.1% | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | · |
| OVID | $212M | -4.0 | 1181.3% | -240.1% | -18.7% | · |
| ASMB | $539M | -61.8 | 153.5% | -8.5% | -5.5% | · |
| TECX | $391M | -5.2 | · | · | -27.7% | · |
| DMAC | $428M | · | · | · | -78.7% | · |
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
重視する指標を選択してください — 上記の「財務諸表」の任意の行の横にある「+」をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。